Analyst Price Targets — AMLX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 25, 2026 11:27 am | — | Guggenheim | $40.00 | $17.00 | TheFly | Amylyx price target raised to $40, named a Best Idea at Guggenheim |
| June 8, 2026 10:55 am | Andrew Fein | H.C. Wainwright | $34.00 | $13.32 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX) |
| April 28, 2026 10:41 am | Graig Suvannavejh | Mizuho Securities | $21.00 | $16.88 | TheFly | Amylyx price target raised to $21 from $19 at Mizuho |
| February 19, 2026 12:16 pm | — | Mizuho Securities | $19.00 | $14.10 | TheFly | Amylyx price target raised to $19 from $18 at Mizuho |
| February 10, 2026 11:10 am | Andrew Fein | H.C. Wainwright | $28.00 | $14.22 | TheFly | Amylyx price target raised to $28 from $20 at H.C. Wainwright |
| October 29, 2025 12:46 pm | — | Mizuho Securities | $16.00 | $13.94 | TheFly | Amylyx price target raised to $16 from $12 at Mizuho |
| October 16, 2025 11:13 am | Joel Beatty | Robert W. Baird | $19.00 | $15.79 | TheFly | Amylyx price target raised to $19 from $10 at Baird |
| September 15, 2025 10:38 am | Seamus Fernandez | Guggenheim | $25.00 | $11.85 | TheFly | Amylyx price target raised to $25 from $17 at Guggenheim |
| June 24, 2025 10:13 am | Seamus Fernandez | Guggenheim | $17.00 | $6.41 | TheFly | Amylyx initiated with a Buy at Guggenheim |
| May 6, 2025 9:00 pm | Marc Goodman | Leerink Partners | $10.00 | $4.65 | TheFly | Leerink upgrades Amylyx on avexitide growth opportunity |
Latest News for AMLX
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026.
Amylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
[url="]Amylyx Pharmaceuticals, Inc.[/url] (NASDAQ: AMLX) (âAmylyxâ or the âCompanyâ) today announced two poster presentations at the upcoming Endocrine
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AMLX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.